Skip to main content
. 2016 Aug 6;51(3):202–211. doi: 10.1007/s13139-016-0439-4

Fig. 1.

Fig. 1

The schematic of a multifunctional PSMA-targeted endoradio-/chemotherapy with and without pre-targeting antiandrogen. (a) The androgen binds to AR, and this complex inactivates the PSMA enhancer region of the FOLH1 gene. (b) Enzalutamide competitively inhibits androgen binding to AR, and the PSMA enhancer region of the FOLH1 gene is activated. (c) Common PSMA-targeted therapy. (d) PSMA-targeted therapy with prior pre-targeting by antiandrogens